{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=interferon+alfa-2a&page=5", "query": { "intervention": "interferon alfa-2a", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 161, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=interferon+alfa-2a&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=interferon+alfa-2a&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T09:35:47.524Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05729139", "title": "Cemiplimab/Peg-Interferon-α in Advanced CSCC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "Squamous Cell Carcinoma", "Advanced Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cemiplimab-Rwlc", "type": "DRUG" }, { "name": "PEG-IFN alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-07", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2023-08-09", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05729139" }, { "nct_id": "NCT00003172", "title": "Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-12", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 24, "location_summary": "Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003172" }, { "nct_id": "NCT00038376", "title": "Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, T-Cell", "Mycosis Fungoides", "Hematologic Neoplasms" ], "interventions": [ { "name": "Isotretinoin (Accutane)", "type": "DRUG" }, { "name": "Interferon Alpha", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "1990-05-08", "completion_date": "2005-06-30", "has_results": false, "last_update_posted_date": "2018-10-29", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038376" }, { "nct_id": "NCT01066819", "title": "PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "Peginterferon alfa-2b [PegIntron®]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1656, "start_date": "2008-01", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 105, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01066819" }, { "nct_id": "NCT01425970", "title": "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "INX-08189", "type": "DRUG" }, { "name": "Placebo matching with INX-08189", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 210, "start_date": "2012-05", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 6, "location_summary": "Anaheim, California • La Jolla, California • San Francisco, California + 3 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425970" }, { "nct_id": "NCT01259817", "title": "Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk Polycythemia Vera", "High Risk Essential Thrombocythemia" ], "interventions": [ { "name": "PEGASYS", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Hoffman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2011-09", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259817" }, { "nct_id": "NCT01479868", "title": "A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Genotype-1" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Pegylated interferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 109, "start_date": "2011-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479868" }, { "nct_id": "NCT04439539", "title": "A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "PegIFN-alpha-2a", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "Tenofovir alafenamide", "type": "DRUG" }, { "name": "JNJ-56136379", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2020-09-14", "completion_date": "2024-02-13", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 3, "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania • Seattle, Washington", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439539" }, { "nct_id": "NCT01888900", "title": "New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Chronic Hepatitis C", "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "DUAL", "type": "DRUG" }, { "name": "QUAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2013-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888900" }, { "nct_id": "NCT01519960", "title": "A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 165, "start_date": "2012-07-11", "completion_date": "2021-10-18", "has_results": true, "last_update_posted_date": "2022-11-18", "last_synced_at": "2026-11-15T09:35:47.524Z", "location_count": 6, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519960" } ] }